Fremanezumab versus placebo for migraine prevention in patients with documented failure to up to four migraine preventive medication classes (FOCUS): a randomised, double-blind, placebo-controlled, phase 3b trial

Author(s):: Ferrari, M.D. (0000-0001-9691-9449); Diener, H.C.; Ning, X.P.; Galic, M.; Cohen, J.M.; Yang, R.H.; Mueller, M.; Ahn, A.H.; Schwartz, Y.C.; Grozinski-Wolff, M.; Janka, L.; Ashina, M.

Published: 2019
Publication type: Article / Letter to editor

Date issued: 2019-09-21
Language: English
Is part of: Lancet (2019), Vol. 394, no. 10203, p. 1030-1040
hdl: 1887/120634
doi: 10.1016/S0140-6736(19)31946-4